Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED - Investor Relations & Filings

Listed IPO Mar 2005
Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,304 across all filing types
Latest filing 2026-04-27 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PYC · 2 venues

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PYC 6 pages 18.5KB
Share Issue/Capital Change Classification · 85% confidence The document is ASX Appendix 2A – an application for quotation of newly issued securities following exercise of options/convertible securities. It details the number and class of securities to be quoted, issue date, and post-issue capital structure. This is a corporate action related to issuing and quoting additional shares, matching the “Share Issue/Capital Change” category (SHA).
2026-04-27 English
Exercise of Options and Cleansing Notice 2 pages 226.7KB
Share Issue/Capital Change Classification · 98% confidence The document is an ASX announcement by PYC Therapeutics Limited detailing the issuance of 250,000 new ordinary shares upon exercise of unlisted options and providing a cleansing notice under Section 708A of the Corporations Act. It refers to issuing shares, Appendix 2A quotation for the new shares, and compliance statements. This clearly falls under announcements of new share issues / capital structure changes, matching the 'Share Issue/Capital Change' category (Code: SHA).
2026-04-27 English
Orphan Drug Designation Granted for RP11 by EMA 2 pages 220.4KB
Regulatory Filings Classification · 92% confidence The document is a corporate ASX announcement providing a regulatory update about the European Medicines Agency granting Orphan Drug Designation for the company’s drug candidate. It does not report financial results (not an ER or IR), is not a transcript, not a board change, not a dividend notice, not a capital raise, and not a meeting or voting document. It is a general regulatory announcement and thus best fits the fallback category “Regulatory Filings” (RNS).
2026-04-26 English
ADOA Program - SRC Approve Progression to Multi-Dose Study 3 pages 385.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 15 April 2026 from PYC Therapeutics Limited regarding the progression of a clinical trial phase for their investigational drug candidate PYC-001. It discusses the Safety Review Committee's approval to move from a single ascending dose study to a multiple ascending dose study. The content focuses on clinical trial progress and future study plans, with no financial data, regulatory certifications, or detailed financial reports included. The document is relatively short (5665 characters) and reads as a corporate announcement about clinical development progress rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation or call transcript either. The best fitting category is Regulatory Filings (RNS) as a general announcement about clinical trial progress and company updates that do not fit other specific categories.
2026-04-14 English
Change in substantial holding 3 pages 243.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder in PYC Therapeutics Limited, including dates of changes and dilution events. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2026-03-31 English
PKD - Presentation at World Congress of Nephrology 3 pages 9.2MB
Investor Presentation Classification · 95% confidence The document is an announcement dated 27 March 2026 from PYC Therapeutics Limited about a presentation at the World Congress of Nephrology regarding their drug candidate PYC-003 for Polycystic Kidney Disease. It includes detailed information about the clinical trial progress, drug mechanism, and future study plans. The document states that a copy of the poster presentation is attached to the announcement, indicating this is a communication about a presentation rather than the presentation itself. The content is focused on clinical and scientific updates rather than financial data or regulatory filings. There is no indication that this is a financial report, earnings release, regulatory filing, or management discussion. The document is a detailed investor and public update on a scientific presentation, which fits best under Investor Presentation (IP) as it provides detailed information for investors about the company's drug development progress and clinical trial data. The document length (9439 characters) supports it being a full announcement rather than a brief notice or certification. Therefore, the most appropriate classification is Investor Presentation (IP).
2026-03-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.